|
1
|
Finn L, Markovic SN and Joseph RW: Therapy
for metastatic melanoma: The past, present, and future. BMC Med.
10(23)2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Arnold M, Singh D, Laversanne M, Vignat J,
Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC and Bray
F: Global burden of cutaneous melanoma in 2020 and projections to
2040. JAMA Dermatol. 158:495–503. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Miller AJ and Mihm MC Jr: Melanoma. N Engl
J Med. 355:51–65. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rosenberg SA, Lotze MT, Yang JC, Topalian
SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan
WM, Seipp CA, et al: Prospective randomized trial of high-dose
interleukin-2 alone or in conjunction with lymphokine-activated
killer cells for the treatment of patients with advanced cancer. J
Natl Cancer Inst. 85:622–632. 1993.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bronte V and Mocellin S: Suppressive
influences in the immune response to cancer. J Immunother. 32:1–11.
2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2001.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Okazaki T, Okazaki IM, Wang J, Sugiura D,
Nakaki F, Yoshida T, Kato Y, Fagarasan S, Muramatsu M, Eto T, et
al: PD-1 and LAG-3 inhibitory co-receptors act synergistically to
prevent autoimmunity in mice. J Exp Med. 208:395–407.
2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fourcade J, Sun Z, Pagliano O, Chauvin JM,
Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S,
et al: PD-1 and Tim-3 regulate the expansion of tumor
antigen-specific CD8+ T cells induced by melanoma
vaccines. Cancer Res. 74:1045–1055. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lines JL, Pantazi E, Mak J, Sempere LF,
Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS
and Noelle R: VISTA is an immune checkpoint molecule for human
T-cells. Cancer Res. 74:1924–1932. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hanaizi Z, van Zwieten-Boot B, Calvo G,
Lopez AS, van Dartel M, Camarero J, Abadie E and Pignatti F: The
European medicines agency review of ipilimumab (Yervoy) for the
treatment of advanced (unresectable or metastatic) melanoma in
adults who have received prior therapy: Summary of the scientific
assessment of the committee for medicinal products for human use.
Eur J Cancer. 48:237–242. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tarhini AA: Tremelimumab: A review of
development to date in solid tumors. Immunotherapy. 5:215–229.
2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang D, Wang T, Liu J, Yu H, Jiao S, Feng
B, Zhou F, Fu Y, Yin Q, Zhang P, et al: Acid-activatable versatile
micelleplexes for PD-L1 blockade-enhanced cancer photodynamic
immunotherapy. Nano Lett. 16:5503–5513. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ottaviano M, De Placido S and Ascierto PA:
Recent success and limitations of immune checkpoint inhibitors for
cancer: A lesson from melanoma. Virchows Arch. 474:421–432.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chambers CA, Sullivan TJ and Allison JP:
Lymphoproliferation in CTLA-4-deficient mice is mediated by
costimulation-dependent activation of CD4+ T-cells.
Immunity. 7:885–895. 1997.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tivol EA, Borriello F, Schweitzer AN,
Lynch WP, Bluestone JA and Sharpe AH: Loss of CTLA-4 leads to
massive lymphoproliferation and fatal multiorgan tissue
destruction, revealing a critical negative regulatory role of
CTLA-4. Immunity. 3:541–547. 1995.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Waterhouse P, Penninger JM, Timms E,
Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H and Mak TW:
Lymphoproliferative disorders with early lethality in mice
deficient in Ctla-4. Science. 270:985–988. 1995.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Walker LSK and Sansom DM: The emerging
role of CTLA4 as a cell-extrinsic regulator of T cell responses.
Nat Rev Immunol. 11:852–863. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ménard C, Ghiringhelli F, Roux S, Chaput
N, Mateus C, Grohmann U, Caillat-Zucman S, Zitvogel L and Robert C:
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells
in advanced melanoma: Surrogate marker of efficacy of tremelimumab?
Clin Cancer Res. 14:5242–5249. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Phan GQ, Yang JC, Sherry RM, Hwu P,
Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA,
Freezer LJ, et al: Cancer regression and autoimmunity induced by
cytotoxic T lymphocyte-associated antigen 4 blockade in patients
with metastatic melanoma. Proc Natl Acad Sci USA. 100:8372–8377.
2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Malek TR and Castro I: Interleukin-2
receptor signaling: At the interface between tolerance and
immunity. Immunity. 33:153–165. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Reuben JM, Lee BN, Li C, Gomez-Navarro J,
Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G
and Camacho LH: Biologic and immunomodulatory events after CTLA-4
blockade with ticilimumab in patients with advanced malignant
melanoma. Cancer. 106:2437–2444. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ribas A, Comin-Anduix B, Economou JS,
Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB,
Shintaku IP, Glaspy JA, et al: Intratumoral immune cell
infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients
with melanoma undergoing CTLA4 blockade. Clin Cancer Res.
15:390–399. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Robert C, Thomas L, Bondarenko I, O'Day S,
Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al:
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med. 364:2517–2526. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Buchbinder EI and Desai A: CTLA-4 and PD-1
pathways: Similarities, differences, and implications of their
inhibition. Am J Clin Oncol. 39:98–106. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Amarnath S, Mangus CW, Wang JCM, Wei F, He
A, Kapoor V, Foley JE, Massey PR, Felizardo TC, Riley JL, et al:
The PDL1-PD1 axis converts human TH1 cells into regulatory T-cells.
Sci Transl Med. 3(111ra120)2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5(200ra116)2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sun Z, Fourcade J, Pagliano O, Chauvin JM,
Sander C, Kirkwood JM and Zarour HM: IL10 and PD-1 cooperate to
limit the activity of tumor-specific CD8+ T cells.
Cancer Res. 75:1635–1644. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zou W and Chen L: Inhibitory B7-family
molecules in the tumour microenvironment. Nat Rev Immunol.
8:467–477. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kinter AL, Godbout EJ, McNally JP, Sereti
I, Roby GA, O'Shea MA and Fauci AS: The common gamma-chain
cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of
programmed death-1 and its ligands. J Immunol. 181:6738–6746.
2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yang J, Riella LV, Chock S, Liu T, Zhao X,
Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, et al: The
novel costimulatory programmed death ligand 1/B7.1 pathway is
functional in inhibiting alloimmune responses in vivo. J Immunol.
187:1113–1119. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Krönig H, Julia Falchner K, Odendahl M,
Brackertz B, Conrad H, Muck D, Hein R, Blank C, Peschel C, Haller
B, et al: PD-1 expression on Melan-A-reactive T cells increases
during progression to metastatic disease. Int J Cancer.
130:2327–2336. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34.
2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D,
Ferrucci PF, et al: Overall survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 377:1345–1356.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Marconcini R, Spagnolo F, Stucci LS,
Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C,
Cavalieri S, et al: Current status and perspectives in
immunotherapy for metastatic melanoma. Oncotarget. 9:12452–12470.
2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Watanabe N, Gavrieli M, Sedy JR, Yang J,
Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, et
al: BTLA is a lymphocyte inhibitory receptor with similarities to
CTLA-4 and PD-1. Nat Immunol. 4:670–679. 2003.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Murphy KM, Nelson CA and Sedý JR:
Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev
Immunol. 6:671–681. 2006.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Fourcade J, Sun Z, Pagliano O, Guillaume
P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V and
Zarour HM: CD8(+) T cells specific for tumor antigens can be
rendered dysfunctional by the tumor microenvironment through
upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res.
72:887–896. 2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Le Mercier I, Chen W, Lines JL, Day M, Li
J, Sergent P, Noelle RJ and Wang L: VISTA regulates the development
of protective antitumor immunity. Cancer Res. 74:1933–1944.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Monney L, Sabatos CA, Gaglia JL, Ryu A,
Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel
RA, et al: Th1-specific cell surface protein Tim-3 regulates
macrophage activation and severity of an autoimmune disease.
Nature. 415:536–541. 2002.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Anderson AC, Anderson DE, Bregoli L,
Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW,
Hirashima M, et al: Promotion of tissue inflammation by the immune
receptor Tim-3 expressed on innate immune cells. Science.
318:1141–1143. 2007.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
46
|
Sabatos CA, Chakravarti S, Cha E, Schubart
A, Sánchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ and
Kuchroo VK: Interaction of Tim-3 and Tim-3 ligand regulates T
helper type 1 responses and induction of peripheral tolerance. Nat
Immunol. 4:1102–1110. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
47
|
Ngiow SF, von Scheidt B, Akiba H, Yagita
H, Teng MWL and Smyth MJ: Anti-TIM3 antibody promotes T cell
IFN-γ-mediated antitumor immunity and suppresses established
tumors. Cancer Res. 71:3540–3551. 2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Advani R, Flinn I, Popplewell L, Forero A,
Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP,
et al: CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's
lymphoma. N Engl J Med. 379:1711–1721. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Ascierto PA, Melero I, Bhatia S, Bono P,
Sanborn RE, Lipson EJ, Callahan MK, Gajewski T, Gomez-Roca CA, Hodi
FS, et al: Initial efficacy of anti-lymphocyte activation gene-3
(anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in
pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1
therapy. J Clin Orthod. 35 (15 Suppl)(S9520)2017.
|
|
50
|
Wei SC, Levine JH, Cogdill AP, Zhao Y,
Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D and
Allison JP: Distinct cellular mechanisms underlie anti-CTLA-4 and
anti-PD-1 checkpoint blockade. Cell. 170:1120–1133.e17.
2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Rotte A, Jin JY and Lemaire V: Mechanistic
overview of immune checkpoints to support the rational design of
their combinations in cancer immunotherapy. Ann Oncol. 29:71–83.
2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Tarhini A: Immune-mediated adverse events
associated with ipilimumab ctla-4 blockade therapy: The underlying
mechanisms and clinical management. Scientifica (Cairo).
2013(857519)2013.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Michot JM, Bigenwald C, Champiat S,
Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A,
Bahleda R, Hollebecque A, et al: Immune-related adverse events with
immune checkpoint blockade: A comprehensive review. Eur J Cancer.
54:139–148. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Tawbi HA, Schadendorf D, Lipson EJ,
Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas
HJ, Lao CD, De Menezes JJ, et al: Relatlimab and nivolumab versus
nivolumab in untreated advanced melanoma. N Engl J Med. 386:24–34.
2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Olson DJ, Eroglu Z, Brockstein B,
Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J,
Higgs E, et al: Pembrolizumab plus ipilimumab following
anti-PD-1/L1 failure in melanoma. J Clin Oncol. 39:2647–2655.
2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Weber JS, Gibney G, Sullivan RJ, Sosman
JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S,
Fecher L, et al: Sequential administration of nivolumab and
ipilimumab with a planned switch in patients with advanced melanoma
(CheckMate 064): An open-label, randomised, phase 2 trial. Lancet
Oncol. 17:943–955. 2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Shoushtari AN, Wagstaff J, Ascierto PA,
Butler MO, Lao CD, Marquez-Rodas I, Chiarion-Sileni V, Dummer R,
Ferrucci PF, Lorigan P, et al: CheckMate 067: Long-term outcomes in
patients with mucosal melanoma. J Clin Orthod. 38 (15
Suppl)(S10019)2020.
|
|
58
|
Pradeep J, Win TT, Aye SN and
Sreeramareddy CT: Efficacy and safety of immune checkpoint
inhibitors for advanced malignant melanoma: A meta-analysis on
monotherapy vs combination therapy. J Cancer. 13:3091–3102.
2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Amaria RN, Reddy SM, Tawbi HA, Davies MA,
Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, et al:
Neoadjuvant immune checkpoint blockade in high-risk resectable
melanoma. Nat Med. 24:1649–1654. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Hodi FS, Chesney J, Pavlick AC, Robert C,
Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK,
Agarwala SS, et al: Combined nivolumab and ipilimumab versus
ipilimumab alone in patients with advanced melanoma: 2-Year overall
survival outcomes in a multicentre, randomised, controlled, phase 2
trial. Lancet Oncol. 17:1558–1568. 2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Hodi FS, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J,
Dummer R, et al: Nivolumab plus ipilimumab or nivolumab alone
versus ipilimumab alone in advanced melanoma (CheckMate 067):
4-Year outcomes of a multicentre, randomised, phase 3 trial. Lancet
Oncol. 19:1480–1492. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Five-year survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 381:1535–1546.
2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Postow MA, Chesney J, Pavlick AC, Robert
C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK,
Agarwala SS, et al: Nivolumab and ipilimumab versus ipilimumab in
untreated melanoma. N Engl J Med. 372:2006–2017. 2015.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Long GV, Atkinson V, Lo S, Sandhu S,
Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer
RA, et al: Combination nivolumab and ipilimumab or nivolumab alone
in melanoma brain metastases: A multicentre randomised phase 2
study. Lancet Oncol. 19:672–681. 2018.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Wagle N, Emery C, Berger MF, Davis MJ,
Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE,
Hahn WC, et al: Dissecting therapeutic resistance to RAF inhibition
in melanoma by tumor genomic profiling. J Clin Oncol. 29:3085–3096.
2011.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Gorre ME, Mohammed M, Ellwood K, Hsu N,
Paquette R, Rao PN and Sawyers CL: Clinical resistance to STI-571
cancer therapy caused by BCR-ABL gene mutation or amplification.
Science. 293:876–880. 2001.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Ellis LM and Hicklin DJ: Resistance to
targeted therapies: Refining anticancer therapy in the era of
molecular oncology. Clin Cancer Res. 15:7471–7478. 2009.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Johannessen CM, Boehm JS, Kim SY, Thomas
SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP,
Barretina J, et al: COT drives resistance to RAF inhibition through
MAP kinase pathway reactivation. Nature. 468:968–972.
2010.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Montagut C, Sharma SV, Shioda T, McDermott
U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A,
et al: Elevated CRAF as a potential mechanism of acquired
resistance to BRAF inhibition in melanoma. Cancer Res.
68:4853–4861. 2008.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Villanueva J, Vultur A, Lee JT,
Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu
X, Gimotty PA, Kee D, et al: Acquired resistance to BRAF inhibitors
mediated by a RAF kinase switch in melanoma can be overcome by
cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18:683–695.
2010.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Turke AB, Zejnullahu K, Wu YL, Song Y,
Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L,
et al: Preexistence and clonal selection of MET amplification in
EGFR mutant NSCLC. Cancer Cell. 17:77–88. 2010.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043.
2007.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Guix M, Faber AC, Wang SE, Olivares MG,
Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL and Engelman
JA: Acquired resistance to EGFR tyrosine kinase inhibitors in
cancer cells is mediated by loss of IGF-binding proteins. J Clin
Invest. 118:2609–2619. 2008.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Paraiso KHT, Xiang Y, Rebecca VW, Abel EV,
Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, et
al: PTEN loss confers BRAF inhibitor resistance to melanoma cells
through the suppression of BIM expression. Cancer Res.
71:2750–2760. 2011.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Maio M, Grob JJ, Aamdal S, Bondarenko I,
Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT,
et al: Five-year survival rates for treatment-naive patients with
advanced melanoma who received ipilimumab plus dacarbazine in a
phase III trial. J Clin Oncol. 33:1191–1196. 2015.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Eggermont AMM, Chiarion-Sileni V, Grob JJ,
Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA,
Richards JM, et al: Prolonged survival in stage III melanoma with
ipilimumab adjuvant therapy. N Engl J Med. 375:1845–1855.
2016.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Ascierto PA, Del Vecchio M, Robert C,
Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L,
Hamid O, Rutkowski P, et al: Ipilimumab 10 mg/kg versus ipilimumab
3 mg/kg in patients with unresectable or metastatic melanoma: A
randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol.
18:611–622. 2017.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330.
2015.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Weber JS, D'Angelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Larkin J, Minor D, D'Angelo S, Neyns B,
Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao
CD, et al: Overall survival in patients with advanced melanoma who
received nivolumab versus investigator's choice chemotherapy in
CheckMate 037: A randomized, controlled, open-label phase III
trial. J Clin Oncol. 36:383–390. 2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Weber J, Mandala M, Del Vecchio M, Gogas
HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V,
Marquez-Rodas I, et al: Adjuvant nivolumab versus ipilimumab in
resected stage III or IV melanoma. N Engl J Med. 377:1824–1835.
2017.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Ribas A, Puzanov I, Dummer R, Schadendorf
D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD,
et al: Pembrolizumab versus investigator-choice chemotherapy for
ipilimumab-refractory melanoma (KEYNOTE-002): A randomised,
controlled, phase 2 trial. Lancet Oncol. 16:908–918.
2015.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Robert C, Ribas A, Schachter J, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, et al:
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006):
Post-hoc 5-year results from an open-label, multicentre,
randomised, controlled, phase 3 study. Lancet Oncol. 20:1239–1251.
2019.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Schachter J, Ribas A, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus ipilimumab for advanced melanoma: Final
overall survival results of a multicentre, randomised, open-label
phase 3 study (KEYNOTE-006). Lancet. 390:1853–1862. 2017.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Long GV, Atkinson V, Ascierto PA, Robert
C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau
I, et al: Effect of nivolumab on health-related quality of life in
patients with treatment-naïve advanced melanoma: Results from the
phase III CheckMate 066 study. Ann Oncol. 27:1940–1946.
2016.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Schadendorf D, Dummer R, Hauschild A,
Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S,
Puzanov I, et al: Health-related quality of life in the randomised
KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients
with ipilimumab-refractory melanoma. Eur J Cancer. 67:46–54.
2016.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Nosrati A, Tsai KK, Goldinger SM, Tumeh P,
Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R,
et al: Evaluation of clinicopathological factors in PD-1 response:
derivation and validation of a prediction scale for response to
PD-1 monotherapy. Br J Cancer. 116:1141–1147. 2017.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Zhang Y, Liu B, Kotenko S and Li W:
Prognostic value of neutrophil-lymphocyte ratio and lactate
dehydrogenase in melanoma patients treated with immune checkpoint
inhibitors: A systematic review and meta-analysis. Medicine
(Baltimore). 101(e29536)2022.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Gershenwald JE, Scolyer RA, Hess KR,
Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM,
McArthur GA, et al: Melanoma staging: Evidence-based changes in the
American joint committee on cancer eighth edition cancer staging
manual. CA Cancer J Clin. 67:472–492. 2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Balch CM, Gershenwald JE, Soong SJ, Soong
SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit
DG, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Hauschild A, Engel G, Brenner W, Gläser R,
Mönig H, Henze E and Christophers E: S100B protein detection in
serum is a significant prognostic factor in metastatic melanoma.
Oncology. 56:338–344. 1999.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Jury CS, McAllister EJ and MacKie RM:
Rising levels of serum S100 protein precede other evidence of
disease progression in patients with malignant melanoma. Br J
Dermatol. 143:269–274. 2000.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Mårtenson ED, Hansson LO, Nilsson B, von
Schoultz E, Månsson Brahme E, Ringborg U and Hansson J: Serum
S-100b protein as a prognostic marker in malignant cutaneous
melanoma. J Clin Oncol. 19:824–831. 2001.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Janka EA, Várvölgyi T, Sipos Z, Soós A,
Hegyi P, Kiss S, Dembrovszky F, Csupor D, Kéringer P, Pécsi D, et
al: Predictive performance of serum S100B versus LDH in melanoma
patients: A systematic review and meta-analysis. Front Oncol.
11(772165)2021.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Friedman RC, Farh KKH, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Lim LP, Glasner ME, Yekta S, Burge CB and
Bartel DP: Vertebrate microRNA genes. Science.
299(1540)2003.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Lau NC, Lim LP, Weinstein EG and Bartel
DP: An abundant class of tiny RNAs with probable regulatory roles
in Caenorhabditis elegans. Science. 294:858–862. 2001.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Lee RC and Ambros V: An extensive class of
small RNAs in Caenorhabditis elegans. Science. 294:862–864.
2001.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Pfeffer SR, Grossmann KF, Cassidy PB, Yang
CH, Fan M, Kopelovich L, Leachman SA and Pfeffer LM: Detection of
exosomal miRNAs in the plasma of melanoma patients. J Clin Med Res.
4:2012–2027. 2015.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Lin N, Zhou Y, Lian X and Tu Y: Expression
of microRNA-106b and its clinical significance in cutaneous
melanoma. Genet Mol Res. 14:16379–16385. 2015.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Friedman EB, Shang S, de Miera EVS, Fog
JU, Teilum MW, Ma MW, Berman RS, Shapiro RL, Pavlick AC, Hernando
E, et al: Serum microRNAs as biomarkers for recurrence in melanoma.
J Transl Med. 10(155)2012.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Wróblewska JP, Lach MS, Ustaszewski A,
Kulcenty K, Ibbs M, Jagiełło I, Suchorska WM and Marszałek A: The
potential role of selected miRNA in uveal melanoma primary tumors
as early biomarkers of disease progression. Genes (Basel).
11(271)2020.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Tsao SCH, Weiss J, Hudson C, Christophi C,
Cebon J, Behren A and Dobrovic A: Monitoring response to therapy in
melanoma by quantifying circulating tumour DNA with droplet digital
PCR for BRAF and NRAS mutations. Sci Rep. 5(11198)2015.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Girotti MR, Gremel G, Lee R, Galvani E,
Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, et
al: Application of sequencing, liquid biopsies, and patient-derived
xenografts for personalized medicine in melanoma. Cancer Discov.
6:286–299. 2016.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Clark WH Jr, Elder DE, Guerry D IV,
Braitman LE, Trock BJ, Schultz D, Synnestvedt M and Halpern AC:
Model predicting survival in stage I melanoma based on tumor
progression. J Natl Cancer Inst. 81:1893–1904. 1989.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Clemente CG, Mihm MC Jr, Bufalino R,
Zurrida S, Collini P and Cascinelli N: Prognostic value of tumor
infiltrating lymphocytes in the vertical growth phase of primary
cutaneous melanoma. Cancer. 77:1303–1310. 1996.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Mandalà M and Massi D: Tissue prognostic
biomarkers in primary cutaneous melanoma. Virchows Arch.
464:265–281. 2014.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Balch CM, Murad TM, Soong SJ, Ingalls AL,
Halpern NB and Maddox WA: A multifactorial analysis of melanoma:
Prognostic histopathological features comparing Clark's and
Breslow's staging methods. Ann Surg. 188:732–742. 1978.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Lattanzi M, Lee Y, Simpson D, Moran U,
Darvishian F, Kim RH, Hernando E, Polsky D, Hanniford D, Shapiro R,
et al: Primary melanoma histologic subtype: Impact on survival and
response to therapy. J Natl Cancer Inst. 111:180–188.
2019.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Robinson E, Kulkarni PM, Pradhan JS,
Gartrell RD, Yang C, Acs B, Rohr B, Phelps R, Ferringer T, Horst B,
et al: Prediction of distant melanoma recurrence from primary tumor
digital H&E images using deep learning. J Clin Orthod. 37 (15
Suppl)(S9577)2019.
|
|
113
|
Lehmann JM, Holzmann B, Breitbart EW,
Schmiegelow P, Riethmüller G and Johnson JP: Discrimination between
benign and malignant cells of melanocytic lineage by two novel
antigens, a glycoprotein with a molecular weight of 113,000 and a
protein with a molecular weight of 76,000. Cancer Res. 47:841–845.
1987.PubMed/NCBI
|
|
114
|
Lei X, Guan CW, Song Y and Wang H: The
multifaceted role of CD146/MCAM in the promotion of melanoma
progression. Cancer Cell Int. 15(3)2015.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Pacifico MD, Grover R, Richman PI, Daley
FM, Buffa F and Wilson GD: Development of a tissue array for
primary melanoma with long-term follow-up: Discovering melanoma
cell adhesion molecule as an important prognostic marker. Plast
Reconstr Surg. 115:367–375. 2005.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Weinstein D, Leininger J, Hamby C and
Safai B: Diagnostic and prognostic biomarkers in melanoma. J Clin
Aesthet Dermatol. 7:13–24. 2014.PubMed/NCBI
|
|
117
|
Gimotty PA, Van Belle P, Elder DE, Murry
T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P and Guerry
D: Biologic and prognostic significance of dermal Ki67 expression,
mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J
Clin Oncol. 23:8048–8056. 2005.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Ladstein RG, Bachmann IM, Straume O and
Akslen LA: Ki-67 expression is superior to mitotic count and novel
proliferation markers PHH3, MCM4 and mitosin as a prognostic factor
in thick cutaneous melanoma. BMC Cancer. 10(140)2010.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Tu TJ, Ma MW, Monni S, Rose AE, Yee H,
Darvishian F, Polsky D, Berman RS, Shapiro RL, Pavlick AC, et al: A
high proliferative index of recurrent melanoma is associated with
worse survival. Oncology. 80:181–187. 2011.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Kahn HJ, Bailey D and Marks A: Monoclonal
antibody D2-40, a new marker of lymphatic endothelium, reacts with
Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol.
15:434–440. 2002.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Kahn HJ and Marks A: A new monoclonal
antibody, D2-40, for detection of lymphatic invasion in primary
tumors. Lab Invest. 82:1255–1257. 2002.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Niakosari F, Kahn HJ, McCready D,
Ghazarian D, Rotstein LE, Marks A, Kiss A and From L: Lymphatic
invasion identified by monoclonal antibody D2-40, younger age, and
ulceration: Predictors of sentinel lymph node involvement in
primary cutaneous melanoma. Arch Dermatol. 144:462–467.
2008.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Rittling SR and Chambers AF: Role of
osteopontin in tumour progression. Br J Cancer. 90:1877–1881.
2004.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Rudland PS, Platt-Higgins A, El-Tanani M,
Silva Rudland S, Barraclough R, Winstanley JH, Howitt R and West
CR: Prognostic significance of the metastasis-associated protein
osteopontin in human breast cancer. Cancer Res. 62:3417–3427.
2002.PubMed/NCBI
|
|
125
|
Pan HW, Ou YH, Peng SY, Liu SH, Lai PL,
Lee PH, Sheu JC, Chen CL and Hsu HC: Overexpression of osteopontin
is associated with intrahepatic metastasis, early recurrence, and
poorer prognosis of surgically resected hepatocellular carcinoma.
Cancer. 98:119–127. 2003.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Rangel J, Nosrati M, Torabian S, Shaikh L,
Leong SP, Haqq C, Miller JR II, Sagebiel RW and Kashani-Sabet M:
Osteopontin as a molecular prognostic marker for melanoma. Cancer.
112:144–150. 2008.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Thomas NE, Edmiston SN, Alexander A,
Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H,
Gruber SB, From L, et al: Association between NRAS and BRAF
mutational status and melanoma-specific survival among patients
with higher-risk primary melanoma. JAMA Oncol. 1:359–368.
2015.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Cirenajwis H, Lauss M, Ekedahl H, Törngren
T, Kvist A, Saal LH, Olsson H, Staaf J, Carneiro A, Ingvar C, et
al: NF1-mutated melanoma tumors harbor distinct clinical and
biological characteristics. Mol Oncol. 11:438–451. 2017.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74.
2015.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Van Allen EM, Miao D, Schilling B, Shukla
SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger
SM, et al: Genomic correlates of response to CTLA-4 blockade in
metastatic melanoma. Science. 350:207–211. 2015.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Johnson DB, Lovly CM, Flavin M, Panageas
KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, et
al: Impact of NRAS mutations for patients with advanced melanoma
treated with immune therapies. Cancer Immunol Res. 3:288–295.
2015.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Johnson DB, Bordeaux J, Kim JY, Vaupel C,
Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, et al:
Quantitative spatial profiling of PD-1/PD-L1 interaction and
HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in
metastatic melanoma. Clin Cancer Res. 24:5250–2560. 2018.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Johnson DB, Estrada MV, Salgado R, Sanchez
V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS,
Greenplate AR, et al: Melanoma-specific MHC-II expression
represents a tumour-autonomous phenotype and predicts response to
anti-PD-1/PD-L1 therapy. Nat Commun. 7(10582)2016.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Rodig SJ, Gusenleitner D, Jackson DG,
Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C,
Weber JS, et al: MHC proteins confer differential sensitivity to
CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci
Transl Med. 10(eaar3342)2018.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Chowell D, Morris LGT, Grigg CM, Weber JK,
Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, et
al: Patient HLA class I genotype influences cancer response to
checkpoint blockade immunotherapy. Science. 359:582–587.
2018.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Sanlorenzo M, Vujic I, Floris A, Novelli
M, Gammaitoni L, Giraudo L, Macagno M, Leuci V, Rotolo R, Donini C,
et al: BRAF and MEK inhibitors increase PD-1-positive melanoma
cells leading to a potential lymphocyte-independent synergism with
anti-PD-1 antibody. Clin Cancer Res. 24:3377–3385. 2018.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Eggermont AMM, Blank CU, Mandala M, Long
GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A,
Carlino MS, et al: Adjuvant pembrolizumab versus placebo in
resected stage III melanoma. N Engl J Med. 378:1789–1801.
2018.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Rimm DL, Han G, Taube JM, Yi ES, Bridge
JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, et al: A
prospective, multi-institutional, pathologist-based assessment of 4
immunohistochemistry assays for PD-L1 expression in non-small cell
lung cancer. JAMA Oncol. 3:1051–1058. 2017.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Rizk EM, Gartrell RD, Barker LW, Esancy
CL, Finkel GG, Bordbar DD and Saenger YM: Prognostic and predictive
immunohistochemistry-based biomarkers in cancer and immunotherapy.
Hematol Oncol Clin North Am. 33:291–299. 2019.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Harel M, Ortenberg R, Varanasi SK,
Mangalhara KC, Mardamshina M, Markovits E, Baruch EN, Tripple V,
Arama-Chayoth M, Greenberg E, et al: Proteomics of melanoma
response to immunotherapy reveals mitochondrial dependence. Cell.
179:236–250.e18. 2019.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Zhou X, Yu S, Zhao DM, Harty JT, Badovinac
VP and Xue HH: Differentiation and persistence of memory CD8(+) T
cells depend on T cell factor 1. Immunity. 33:229–240.
2010.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Kratchmarov R, Magun AM and Reiner SL:
TCF1 expression marks self-renewing human CD8+ T cells.
Blood Adv. 2:1685–1690. 2018.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Im SJ, Hashimoto M, Gerner MY, Lee J,
Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, et al:
Defining CD8+ T cells that provide the proliferative burst after
PD-1 therapy. Nature. 537:417–421. 2016.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Sade-Feldman M, Yizhak K, Bjorgaard SL,
Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT,
Barzily-Rokni M, et al: Defining T cell states associated with
response to checkpoint immunotherapy in melanoma. Cell.
175:998–1013.e20. 2018.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Hugo W, Zaretsky JM, Sun L, Song C, Moreno
BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G,
et al: Genomic and transcriptomic features of response to anti-PD-1
therapy in metastatic melanoma. Cell. 165:35–44. 2016.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA,
Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, et
al: T-cell-inflamed gene-expression profile, programmed death
ligand 1 expression, and tumor mutational burden predict efficacy
in patients treated with pembrolizumab across 20 cancers:
KEYNOTE-028. J Clin Oncol. 37:318–327. 2019.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Ayers M, Lunceford J, Nebozhyn M, Murphy
E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran
V, et al: IFN-γ-related mRNA profile predicts clinical response to
PD-1 blockade. J Clin Invest. 127:2930–2940. 2017.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Pinato DJ, Howlett S, Ottaviani D, Urus H,
Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, et al:
Association of prior antibiotic treatment with survival and
response to immune checkpoint inhibitor therapy in patients with
cancer. JAMA Oncol. 5:1774–1778. 2019.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Yang H, Xia L, Chen J, Zhang S, Martin V,
Li Q, Lin S, Chen J, Calmette J, Lu M, et al:
Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced
antitumor immunity. Nat Med. 25:1428–1441. 2019.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Altan-Bonnet G and Mukherjee R:
Cytokine-mediated communication: A quantitative appraisal of immune
complexity. Nat Rev Immunol. 19:205–217. 2019.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Eisenring M, vom Berg J, Kristiansen G,
Saller E and Becher B: IL-12 initiates tumor rejection via lymphoid
tissue-inducer cells bearing the natural cytotoxicity receptor
NKp46. Nat Immunol. 11:1030–1038. 2010.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Cristiani CM, Capone M, Garofalo C,
Madonna G, Mallardo D, Tuffanelli M, Vanella V, Greco M, Foti DP,
Viglietto G, et al: Altered frequencies and functions of innate
lymphoid cells in melanoma patients are modulated by immune
checkpoints inhibitors. Front Immunol. 13(811131)2002.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Joshi K, Atwal D, Ravilla R, Pandey Y,
Yarlagadda N, Kakadia S, Makhoul I, Hutchins L and Mahmoud F:
Immunotherapy outcomes in advanced melanoma in relation to age.
Perm J. 24(19.093)2020.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Seidel JA, Otsuka A and Kabashima K:
Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of
action, efficacy, and limitations. Front Oncol.
8(86)2018.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Wei SC, Duffy CR and Allison JP:
Fundamental mechanisms of immune checkpoint blockade therapy.
Cancer Discov. 8:1069–1086. 2018.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Jang SR, Nikita N, Banks J, Keith SW,
Johnson JM, Wilson M and Lu-Yao G: Association between sex and
immune checkpoint inhibitor outcomes for patients with melanoma.
JAMA Netw Open. 4(e2136823)2021.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Anstadt EJ, Chu B, Yegya-Raman N, Han X,
Doucette A, Poirier K, Mohiuddin JJ, Maity A, Facciabene A,
Amaravadi RK, et al: Moderate colitis not requiring intravenous
steroids is associated with improved survival in stage IV melanoma
after anti-CTLA4 monotherapy, but not combination therapy.
Oncologist. 27:799–808. 2022.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Jansen YJL, Rozeman EA, Mason R, Goldinger
SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen
JBAG, Tiainen L, et al: Discontinuation of anti-PD-1 antibody
therapy in the absence of disease progression or treatment limiting
toxicity: Clinical outcomes in advanced melanoma. Ann Oncol.
30:1154–1161. 2019.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Robert C, Ribas A, Hamid O, Daud A,
Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW,
et al: Durable complete response after discontinuation of
pembrolizumab in patients with metastatic melanoma. J Clin Orthod.
36:1668–1674. 2018.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Betof Warner A, Palmer JS, Shoushtari AN,
Goldman DA, Panageas KS, Hayes SA, Bajwa R, Momtaz P, Callahan MK,
Wolchok JD, et al: Long-term outcomes and responses to retreatment
in patients with melanoma treated with PD-1 blockade. J Clin Oncol.
38:1655–1663. 2020.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Waterhouse DM, Garon EB, Chandler J,
McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan
B, et al: Continuous versus 1-year fixed-duration nivolumab in
previously treated advanced non-small-cell lung cancer: CheckMate
153. J Clin Orthod. 38:3863–3873. 2020.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ,
Li SW, Liu N and Yan CX: Immune-related adverse events associated
with anti-PD-1/PD-L1 treatment for malignancies: A meta-analysis.
Front Pharmacol. 8(730)2017.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Santini FC, Rizvi H, Plodkowski AJ, Ni A,
Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF,
Long NM, et al: Safety and efficacy of re-treating with
immunotherapy after immune-related adverse events in patients with
NSCLC. Cancer Immunol Res. 6:1093–1099. 2018.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Lebbé C, Meyer N, Mortier L, Marquez-Rodas
I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA,
Smylie M, et al: Evaluation of two dosing regimens for nivolumab in
combination with ipilimumab in patients with advanced melanoma:
Results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol.
37:867–875. 2019.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Tarhini AA, Lee SJ, Hodi FS, Rao UNM,
Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, et
al: Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus
high-dose interferon alfa-2b for resected high-risk melanoma: North
American intergroup E1609. J Clin Oncol. 38:567–575.
2020.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Betof AS, Nipp RD, Giobbie-Hurder A,
Johnpulle RAN, Rubin K, Rubinstein SM, Flaherty KT, Lawrence DP,
Johnson DB and Sullivan RJ: Impact of age on outcomes with
immunotherapy for patients with melanoma. Oncologist. 22:963–971.
2017.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Zamami Y, Niimura T, Okada N, Koyama T,
Fukushima K, Izawa-Ishizawa Y and Ishizawa K: Factors associated
with immune checkpoint inhibitor-related myocarditis. JAMA Oncol.
5:1635–1637. 2019.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Tan MH, Iyengar R, Mizokami-Stout K, Yentz
S, MacEachern MP, Shen LY, Redman B and Gianchandani R: Spectrum of
immune checkpoint inhibitors-induced endocrinopathies in cancer
patients: A scoping review of case reports. Clin Diabetes
Endocrinol. 5(1)2019.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Wright JJ, Powers AC and Johnson DB:
Endocrine toxicities of immune checkpoint inhibitors. Nat Rev
Endocrinol. 17:389–399. 2021.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Minkis K, Garden BC, Wu S, Pulitzer MP and
Lacouture ME: The risk of rash associated with ipilimumab in
patients with cancer: A systematic review of the literature and
meta-analysis. J Am Acad Dermatol. 69:e121–e128. 2013.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Coleman E, Ko C, Dai F, Tomayko MM, Kluger
H and Leventhal JS: Inflammatory eruptions associated with immune
checkpoint inhibitor therapy: A single-institution retrospective
analysis with stratification of reactions by toxicity and
implications for management. J Am Acad Dermatol. 80:990–997.
2019.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Sibaud V, Meyer N, Lamant L, Vigarios E,
Mazieres J and Delord JP: Dermatologic complications of
anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol.
28:254–263. 2016.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Sibaud V: Dermatologic reactions to immune
checkpoint inhibitors: Skin toxicities and immunotherapy. Am J Clin
Dermatol. 19:345–361. 2018.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Inno A, Metro G, Bironzo P, Grimaldi AM,
Grego E, Di Nunno V, Picasso V, Massari F and Gori S: Pathogenesis,
clinical manifestations and management of immune checkpoint
inhibitors toxicity. Tumori. 103:405–421. 2017.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Kumar V, Chaudhary N, Garg M, Floudas CS,
Soni P and Chandra AB: Current diagnosis and management of immune
related adverse events (irAEs) Induced by immune checkpoint
inhibitor therapy. Front Pharmacol. 8(49)2017.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Bryce J and Boers-Doets CB: Non-rash
dermatologic adverse events related to targeted therapies. Semin
Oncol Nurs. 30:155–168. 2014.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Geisler AN, Phillips GS, Barrios DM, Wu J,
Leung DYM, Moy AP, Kern JA and Lacouture ME: Immune checkpoint
inhibitor-related dermatologic adverse events. J Am Acad Dermatol.
83:1255–1268. 2020.PubMed/NCBI View Article : Google Scholar
|
|
180
|
Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ,
Qiao H, Fahl SP, Conaway MR, Bender TP, Tung KS, Vella AT, et al:
Lymphatic endothelial cells induce tolerance via PD-L1 and lack of
costimulation leading to high-level PD-1 expression on CD8 T cells.
Blood. 120:4772–4782. 2012.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Sano T, Uhara H, Mikoshiba Y, Kobayashi A,
Uchiyama R, Tateishi K, Yamamoto H and Okuyama R: Nivolumab-induced
organizing pneumonia in a melanoma patient. Jpn J Clin Oncol.
46:270–272. 2016.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Nakashima K, Naito T, Omori S, Yoshikawa
S, Endo M, Kiyohara Y and Takahashi T: Organizing pneumonia induced
by nivolumab in a patient with metastatic melanoma. J Thorac Oncol.
11:432–433. 2016.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Koelzer VH, Rothschild SI, Zihler D, Wicki
A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A and Mertz
KD: Systemic inflammation in a melanoma patient treated with immune
checkpoint inhibitors-an autopsy study. J Immunother Cancer.
4(13)2016.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Watanabe S, Kimura H, Takato H, Waseda Y,
Hara J, Sone T, Abo M, Maeda S, Matsushita T and Kasahara K: Severe
pneumonitis after nivolumab treatment in a patient with melanoma.
Allergol Int. 65:487–489. 2016.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Nishino M, Sholl LM, Hatabu H, Ramaiya NH
and Hodi FS: Anti-PD-1-related pneumonitis during cancer
immunotherapy. N Engl J Med. 373:288–290. 2015.PubMed/NCBI View Article : Google Scholar
|
|
186
|
Mir MA: T-cell costimulation and its
applications in diseases. Dev Costimulatory Mol Immunother Dis.
29:255–292. 2015.
|
|
187
|
Tarazona R, Duran E and Solana R: Natural
killer cell recognition of melanoma: New clues for a more effective
immunotherapy. Front Immunol. 6(649)2015.PubMed/NCBI View Article : Google Scholar
|
|
188
|
Rieth J and Subramanian S: Mechanisms of
intrinsic tumor resistance to immunotherapy. Int J Mol Sci.
19(1340)2018.PubMed/NCBI View Article : Google Scholar
|
|
189
|
Fisher DT, Appenheimer MM and Evans SS:
The two faces of IL-6 in the tumor microenvironment. Semin Immunol.
26:38–47. 2014.PubMed/NCBI View Article : Google Scholar
|
|
190
|
O'Donnell JS, Long GV, Scolyer RA, Teng
MWL and Smyth MJ: Resistance to PD1/PDL1 checkpoint inhibition.
Cancer Treat Rev. 52:71–81. 2017.PubMed/NCBI View Article : Google Scholar
|
|
191
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI View Article : Google Scholar
|
|
192
|
Ahn CS and Metallo CM: Mitochondria as
biosynthetic factories for cancer proliferation. Cancer Metab.
3(1)2015.PubMed/NCBI View Article : Google Scholar
|
|
193
|
O'Donnell JS, Teng MWL and Smyth MJ:
Cancer immunoediting and resistance to T cell-based immunotherapy.
Nat Rev Clin Oncol. 16:151–167. 2019.PubMed/NCBI View Article : Google Scholar
|
|
194
|
DeBerardinis RJ and Chandel NS:
Fundamentals of cancer metabolism. Sci Adv.
2(e1600200)2016.PubMed/NCBI View Article : Google Scholar
|
|
195
|
Robey IF, Lien AD, Welsh SJ, Baggett BK
and Gillies RJ: Hypoxia-inducible factor-1alpha and the glycolytic
phenotype in tumors. Neoplasia. 7:324–330. 2005.PubMed/NCBI View Article : Google Scholar
|
|
196
|
Franco F, Jaccard A, Romero P, Yu YR and
Ho PC: Metabolic and epigenetic regulation of T-cell exhaustion.
Nat Metab. 2:1001–1012. 2020.PubMed/NCBI View Article : Google Scholar
|
|
197
|
Jiang Y, Li Y and Zhu B: T-cell exhaustion
in the tumor microenvironment. Cell Death Dis.
6(e1792)2015.PubMed/NCBI View Article : Google Scholar
|
|
198
|
Sirico M, D'Angelo A, Gianni C, Casadei C,
Merloni F and De Giorgi U: Current state and future challenges for
PI3K inhibitors in cancer therapy. Cancers (Basel).
15(703)2023.PubMed/NCBI View Article : Google Scholar
|
|
199
|
Peng W, Chen JQ, Liu C, Malu S, Creasy C,
Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al: Loss of
PTEN promotes resistance to T cell-mediated immunotherapy. Cancer
Discov. 6:202–216. 2016.PubMed/NCBI View Article : Google Scholar
|
|
200
|
Li X, Wenes M, Romero P, Huang SCC, Fendt
SM and Ho PC: Navigating metabolic pathways to enhance antitumour
immunity and immunotherapy. Nat Rev Clin Oncol. 16:425–441.
2019.PubMed/NCBI View Article : Google Scholar
|
|
201
|
Marin-Acevedo JA, Kimbrough EO and Lou Y:
Next generation of immune checkpoint inhibitors and beyond. J
Hematol Oncol. 14(45)2021.PubMed/NCBI View Article : Google Scholar
|
